Skip to main content
Equibles
RAPP logo

RAPP · Rapport Therapeutics, Inc.

Track RAPP — free

Use RAPP with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research RAPP.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$33.45 +1.26 (+3.91%)
Russell 2000 member Rebalance outlook locked
Market Cap
$1.63B
Shares
47.98M
Volume · Oct 5 198.87K Avg daily vol (3M) 378.16K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$32.19 Open$32.22 Day$31.53–32.71 52W close$24.37–52.50 Avg vol 30d432K Short int2.2M · 4.7% float · 7.9d Short vol52% Last earningsSep 22, 2026 DataJun 2024–Oct 2026 Filing10-Q · Aug 5

Up next

Next earnings call
Jan 8, 2027 Est · unconfirmed · in 13 wks
Latest filing: 10-Q
filed Aug 5, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$137.16M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-6.0%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$436.08M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+33.9%
Year over year · more shares
Price change (1Y)
+12.7%
Trailing year
Short interest
4.7%
Latest settlement · 7.9 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Weak Sentiment Neutral Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 15.5 · calm Equity put/call 0.59
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −10%
below
Price vs 50-day avg −26%
below
RSI (14) 24
oversold
MACD trend Negative
52-week position 28%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return −30%
trailing
6-month return −11%
trailing
YTD return +6%
this year
Relative strength −23%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $43 › 200d $36 — 50d above 200d
Institutional flow Flat
2 of 160 funds reported for Sep 30 · net 0 sh shares
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
4.69% of float · ▲ +0.6% MoM · 7.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
160 holders — near 2-yr high, broad support
Squeeze score 51
elevated · 0–100
Fundamentals
Fair
EPS growth +24%
Y/Y
Free cash flow $-88.1M
Quant / Vol
risk profile
Very High
Volatility 57%
annualized · 1-yr
Max drawdown −39%
past year
ATR 7.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 4 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−10% Bearish
Price vs 50-day avg
−26% Bearish
RSI (14)
24 Neutral
MACD trend
Negative Bearish
52-week position
28% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $43 › 200d $36 — 50d above 200d
Institutional flow Flat
2 of 160 funds reported for Sep 30 · net 0 sh shares
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
4.69% of float · ▲ +0.6% MoM · 7.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
160 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $24 Now $32 · 28% Range high $53
vs 200-day avg -10% vs 50-day avg -26%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
RAPP
Rapport Therapeutics, Inc.
this stock
$1.63B +6.1% — — 4.7%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $133.37B +11.1% +46.2% 30.7 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.13B -5.9% +20.8% 19.5 2.5%
MRNA
Moderna, Inc.
 $79.40B +589.1% +4.3% — 8.2%
CSLLY
Csl Ltd
 $61.25B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders
Holders
160
% held
106.9%
Reported
2 of 160
Top holder
FMR LLC
Held Float
View
Held by Funds
Fund positions
187
View
Short & Settlement
Short Interest Rising
Shares short
2.2M
Days to cover
7.9d
Change
+14.3K sh
View
Short Volume
Short vol %
52%
As of
Oct 5, 2026
Short Total
View
Fails to Deliver
FTD shares
894
Value
$43.5K
As of
Sep 3, 2026
View
Off-Exchange
Off-exchange %
41.7%
Week of
Aug 31, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-111.5M
EPS diluted
$-2.86
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 5, 2026
This year
13
View
Proposed Sales
Value
$330.2K
Shares
10.0K
Filed
Sep 30, 2026
View
Earnings & Events
Webcasts
Last webcast
Sep 22, 2026
View

Performance

5D 20D 120D MTD YTD
RAPP -3.7% -29.7% -11.0% -4.2% +6.1%
SPY +1.2% +0.6% +11.6% +1.6% +13.6%
vs SPY -4.9% -30.3% -22.5% -5.8% -7.5%
Key facts CIK 2012593 CUSIP 75383L102 13F (30d) 4 filings 4 filers Visit website Investor relations